Arbutus could benefit from Big Pharma bird flu vaccines: Jefferies

Posted on by wpadmin
A doctor in blue gloves holding a bottle with vaccine vial of H5N1.Bird flu vaccine. The concept of medicine, healthcare and science.

SyhinStas/iStock via Getty Images

Jefferies sees Arbutus (NASDAQ:ABUS) potentially benefitting from vaccines being developed by Moderna (MRNA) and Pfizer (PFE)/GSK (GSK)/CureVac (CVAC) for H5N1 avian flu.

The investment firm noted that Moderna (MRNA) and Pfizer (PFE), along with Pfizer (

Leave a Reply

Your email address will not be published. Required fields are marked *